EW
$87.23+2.44%
as of close, Oct 5, 2026
☾ AH $87.23 +2.44%
Edwards Lifesciences CorporationStock · HealthcareS&P 500 Equal Weight 0.2%S&P 500 0.08%Russell 1000 0.07%US Stock Market 0.07%Russell 3000 0.07%MSCI World 0.06%MSCI ACWI 0.05%
EW — Edwards Lifesciences Corporation price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeSEEEE
30.040.050.060.070.080.090.0100.0110.0120.0050.0M100.0M$87.23—20162019202120242026
2026-10-05
Price$87.23
MA20$87.38
MA50$83.65
Vol13.7M
Key stats#
Price data
- Price
- $87.23
- YTD price return
- +2.32%
- YTD total return
- +2.32%
- Next earnings
- Oct 29, 2026
- Market cap
- 50.3B
- Enterprise value
- 46.8B
- Shares outstanding
- 576.4M
- 52W low
- $72.30
- 52W high
- $96.29
- From 52W high
- -9.41%
- From 52W low
- +20.65%
- 52W range
- 62%
- Beta
- 0.84
Volume
- Rel volume
- 1.02×
- 30D volume
- 3.2M
- 30D $ vol
- 284.9M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$54K
- Insider net 3M
- −$4.5M
- Insider net 1Y
- −$21.3M
Form 4 transactions by trade date, as filed; latest on file 2026-09-11.
Fundamentals
- Sales (ttm)
- 6.5B
- Sales/share
- $11.30
- EPS (ttm)
- $1.73
- FCF (ttm)
- 1.4B
- FCF/share
- $2.49
- Book value/share
- $18.42
- Net margin
- 15.43%
- ROE
- 9.46%
- ROA
- 7.25%
- Debt / equity
- 0.06×
- Current ratio
- 4.52
Growth (CAGR, ttm) · 10Y
- Sales
- +14.56%+15.29%+5.75%+9.03%
- Net income
- -75.80%-10.24%-7.23%+6.64%
- FCF
- +144.00%+26.85%+6.41%+11.67%
- Shares
- -1.82%-1.76%-1.55%-1.02%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -75.15%-8.52%-5.80%+7.92%
- Sales/share
- +16.69%+17.36%+7.41%+10.16%
- FCF/share
- +148.53%+29.12%+8.09%+12.82%
- Book value/share
- +2.56%+20.65%+17.47%+16.89%
- Price
- +13.99%+6.50%-4.33%+8.18%
- Total return
- +13.99%+6.50%-4.33%+8.18%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 50.5×
- P/OI (ttm)
- 34.7×
- Fwd P/E
- 25.2×
- P/S (ttm)
- 7.7×
- P/B (mrq)
- 4.7×
- P/FCF (ttm)
- 35.1×
- EV/EBITDA (fy)
- 29.0×
- EV/Sales (ttm)
- 7.2×
- FCF yield (ttm)
- 2.85%
- Buyback yield (realized, 1y)
- 1.82%
- Shareholder yield (realized, 1y)
- 1.82%
- Buyback yield (cash, ttm)
- 2.40%
- Shareholder yield (cash, ttm)
- 2.40%
Vs own 10Y history
- P/E
- 76th
- P/OI
- 47th
- P/S
- 20th
- P/B
- 15th
- P/FCF
- 6th
Bar = where today’s multiple sits in EW’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-05#
1D
+2.44%
5D
+0.46%
1M
-2.97%
3M
-7.57%
YTD
+2.32%
1Y
+13.18%
5Y
-19.85%
Recent filings#
- Sep 11Insider sale · Lippis Daniel J. (CVP, TAVR) sold 619 shares for $54K at $87.51 under a 10b5-1 plan
- Aug 31Insider sale · Dahl Andrew M. (SVP, Corporate Controller) sold 544 shares for $50K at $91.06
- Aug 28Insider sale · Bruls Annette (CVP, EMEACLA) sold 2,644 shares for $238K at $89.98
- Aug 288-K · Directors or officers; compensation
- Aug 26Insider sale · Chopra Daveen (CVP, TMTT, Surgical & IHFM) sold 31,800 shares for $2.9M at $90.99–$91.76
Financial statements
Open full EW financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | -0.54% | +0.02% |
| JNJ | Johnson & Johnson | -8.10% | -1.21% |
| ABBV | AbbVie Inc. | +3.63% | +1.12% |
| MRK | Merck & Co. Inc. | -7.18% | -3.30% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -4.67% | +1.80% |
| TMO | Thermo Fisher Scientific Inc. | +10.26% | +3.35% |
| AMGN | Amgen Inc. | -7.83% | -0.01% |
| GILD | Gilead Sciences Inc. | -4.22% | -0.08% |
